LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
M-J. Ahn(Samsung Medical Center), Isamu Okamoto(Kyushu University Hospital), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Hidetoshi Hayashi(Kindai University), M. Pérol(Centre Léon Bérard), Robin Cornelissen(Erasmus MC Cancer Institute), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Elena Poddubskaya, Jacob Sands(Harvard University), Satoru Kitazono(The Cancer Institute Hospital), Deise Uema(Daiichi Sankyo (United States)), Richard D. Hall(University of Virginia Health System), Aaron Lisberg(APLA Health), Shunichi Sugawara(Sendai Kousei Hospital), Nicolas Girard(Institut Curie), Yong Zhang(Lanzhou University), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes), David Vicente Baz(Hospital Universitario Virgen Macarena), Céline Mascaux(Hôpitaux Universitaires de Strasbourg)
Cited by 56
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k